2023
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration
Rein S, Lodi S, Logan R, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein M, Young J, Jarrin I, Monforte A, Tavelli A, Meyer L, Tran L, Gill M, Lang R, Surial B, Haas A, Justice A, Rentsch C, Phillips A, Sabin C, Miro J, Trickey A, Ingle S, Sterne J, Hernán M, Collaboration A. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. The Lancet HIV 2023, 10: e723-e732. PMID: 37923486, PMCID: PMC10695103, DOI: 10.1016/s2352-3018(23)00233-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultCardiovascular DiseasesHIV InfectionsHIV Integrase InhibitorsHumansIntegrasesNorth AmericaConceptsART-experienced individualsCardiovascular eventsTarget trialsART regimensRisk ratioTreatment strategiesRisk differenceEligibility criteriaIntegrase strand transfer inhibitor useAntiretroviral Therapy Cohort CollaborationIntegrase strand transfer inhibitorsPooled logistic modelART-naive individualsHIV RNA measurementsHIV-CAUSAL CollaborationNational InstituteStrand transfer inhibitorsLogistic regression modelsART regimenCohort CollaborationAntiretroviral therapyInhibitor useBlood pressureINSTI useClinical data
2022
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCohort StudiesDarunavirEuropeFemaleHIV InfectionsHIV Integrase InhibitorsHumansMaleMiddle AgedNorth AmericaRaltegravir PotassiumRilpivirineConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National Institutes